Phase I/II Study to OVERCOME Resistance to PD-1/PD-L1 Inhibitor Immunotherapy in Advanced Non-Small Cell Lung Cancer - I-OVERCOME Trial
Latest Information Update: 03 Jun 2022
At a glance
- Drugs Nivolumab (Primary) ; Sapanisertib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms I-OVERCOME
Most Recent Events
- 01 Sep 2021 New trial record